Les maladies à prion font partie des maladies neurodégénératives. L’agent responsable est la protéine prion PrPSc. La conversion de la forme cellulaire nativePrPC en forme pathologique PrPSc et son agrégation sous forme des fibres amyloïdeconstituent des éléments clés de la physiopathologie des maladies à prion. Pourtant,les mécanismes contrôlant/favorisant cette conversion sont très mal connus. Chez lalevure Saccharomyces cerevisiae, il n’existe pas d’homologue de la protéine PrP,mais des protéines se comportant comme des prions existent, telle que Sup35p quiest responsable du prion [PSI+] ou encore la protéine Ure2p qui est responsable duprion [URE3]. Lors d’études antérieures à cette thèse, le laboratoire a isolé la 6AP etle GA, des molécules actives contre les prions de levure [PSI+] et [URE3] et contre leprion de mammifère PrPSc dans des tests cellulaires ainsi que in vivo dans unmodèle murin pour les maladies à prion. Ces résultats démontrent au moins certainsdes mécanismes de prionisation sont conservés de la levure aux mammifères.L’équipe a ensuite montré que la 6AP et le GA étaient des inhibiteurs spécifiques etcompétitifs de l’activité chaperon de protéines du ribosome (ou PFAR pour ProteinFolding Activity of the Ribosome). Ces résultats suggéraient donc que l’activité PFARreprésente un nouveau mécanisme de prionisation conservé de la levure auxmammifères. Par ailleurs, la 6AP et le GA s’étant révélées actives dans des modèlespour d’autres maladies neurodégénératives à fibres amyloïdes, l’activité PFARpourrait également être un acteur physiopathologique majeur de ces protéinopathies.Ma thèse avait deux objets : tester l’implication de l’activité PFAR dans l’apparitionet/ou la propagation des prions et enfin identifier de nouvelles molécules antiprion etcomprendre leurs mécanismes d’action. Mes résultats montrent que l’activité PFARjoue bien un rôle dans la propagation des prions de levure. En effet, l’enrichissementen PFAR favorise l’apparition spontanée du prion [PSI+]. Il conduit également à uneinstabilité accrue de ce même prion. Ainsi, l’activité PFAR ressemble à celle duchaperon de protéine Hsp104p, une protéine indispensable au maintien et à lapropagation de tous les prions de levure, mais qui n’a pas d’homologue chez lesmammifères. Mes résultats suggèrent que les activités PFAR et Hsp104p sontpartiellement redondantes pour le maintien des prions chez la levure et que, chez lesmammifères, seule l’activité PFAR jouerait ce rôle. Parallèlement, nous avonsidentifié de nouvelles familles de molécules antiprion, actives tant contre les prionsde levure que de mammifères. Ces molécules inhibent toutes l’activité PFAR. Nosrésultats contribuent ainsi à une meilleure compréhension des mécanismes deprionisation. Ils indiquent également que l’activité PFAR est une cible thérapeutiqueprometteuse pour les maladies à prion, mais aussi probablement pour d’autresprotéinopathies beaucoup plus fréquentes. / Prion diseases are considered neurodegenerative diseases. The incriminated agentis the prion protein PrPSc. The conversion of PrP from its native conformation PrPC tothe pathologic form PrPSc is the major element of the pathogenesis of prion diseases.However, the mechanisms involved in this conversion are poorly understood. In theyeast Saccharomyces cerevisiae, there is no counterpart of the PrP protein. Howeverproteins acting as prion do exist in yeast, such as the Sup35 protein responsible forthe prion [PSI+], or the Ure2 protein responsible for the prion [URE3]. In previousstudies, our team isolated two compounds, 6AP and GA, which are active against theyeast prions [PSI+] and [URE3 ] and against the mammalian prion PrPSc in cellbasedassays as well as in vivo in a mouse model for prion diseases. These resultsdemonstrated that the prionisation mechanisms are at least partially conserved fromyeast to mammals. 6AP and GA specific and competitive inhibitors of the ProteinFolding Activity of the Ribosome (PFAR) thereby showing that the PFAR is oneconserved mechanism of the prionisation. Moreover, 6AP and GA have been provenactive against other amyloid diseases thus placing the PFAR as a key player in thepathophysiology of protein folding diseases. My thesis aims were to test theinvolvement of the PFAR in the initiation and / or propagation of prion, to identify newantiprion molecules and to understand their mechanisms of action. My results showthat the PFAR plays a central role in the yeast prion propagation. Indeed, PFARenrichment promotes the spontaneous appearance of the prion [PSI+] and at thesame time leads to an increased instability of the same prion. Thus, PFAR activityresembles the yeast Hsp104p chaperone protein activity in the maintenance andpropagation of all yeast prions. My results suggest that the PFAR and Hsp104pactivity are partially redundant and that only the PFAR should play this role inmammals. Meanwhile, we have identified new antiprion drugs that are active againstboth yeast and mammal’s prions. These compounds are all inhibitors of the PFAR.Our results contribute to a better understanding of the prionisation mechanisms andindicate that the PFAR is a promising therapeutic target for prion diseases andprobably also for common protein folding diseases.Keywords: prion, yeast, ribosome, protein chaperon, Hsp104

La conversion de la protéine prion cellulaire PrPC en une isoforme pathologique, la protéine prion scrapie PrPSc, est à l'origine d'un groupe de maladies neurodégénératives, les Encéphalopathies Spongiformes Transmissibles (EST). De nombreux travaux indiquent que la toxicité de la PrPSc implique une déviation de la fonction normale de la PrPC, cependant le rôle physiologique de la protéine prion n’est que partiellement compris. Dans ce travail, nous nous sommes attachés à identifier des voies de signalisation mobilisées par la PrPC qui pourraient à la fois rendre compte du rôle de cette protéine dans le développement du système nerveux et être impliquées dans la pathogénèse des EST. Nous montrons que la protéine prion contrôle l’activité de la voie Notch, une voie de signalisation qui joue un rôle majeur dans le développement mais également dans l’homéostasie du système nerveux central et la plasticité synaptique. Dans des modèles ex vivo et in vivo d’EST, nous mettons en évidence une diminution de l’activité de la voie Notch, ainsi que de l’expression des récepteurs de la famille Eph - connus pour leur implication dans l’activité synaptique. Cette diminution des Eph est retrouvée dans des cellules dépourvues de PrPC. Ainsi, l’observation d’un profil similaire entre la perte d’expression de la PrPC et l’infection par les prions renforce l’idée d’une déviation de la fonction normale de la PrPC par la PrPSc. Des inhibiteurs de l’activité histone désacétylase (HDAC) permettent de rétablir l’expression des acteurs de la voie Notch et des récepteurs Eph aussi bien dans les cellules déplétées en PrPC que dans celles infectées par les prions, suggérant que des mécanismes épigénétiques sont impliqués dans le contrôle transcriptionnel de ces gènes par la protéine prion. Ce travail fournit les bases pour évaluer un effet bénéfique des inhibiteurs de HDAC dans un modèle de souris infectées par les prions et ainsi déterminer si les HDAC pourraient constituer de nouvelles cibles thérapeutiques pour combattre les EST. / The conversion of the cellular prion protein PrPC into a pathogenic isoform, the scrapie prion protein PrPSc, lies at the root of a group of neurodegenerative disorders known as Transmissible Spongiform Encephalopathies (TSEs). Several lines of evidence indicate that PrPSc-mediated toxicity involves a subversion of PrPC normal function, however, our knowledge of PrPC physiological role is still far from complete. In this work, we sought to identify signalling pathways mobilized by PrPC that could accommodate both its role in central nervous system development and its implication in TSE pathogenesis. We show that the prion protein controls the activity of the Notch pathway, which plays an overriding role during embryonic development as well as central nervous system homeostasis and synaptic plasticity. In both ex vivo and in vivo models of TSE, we monitored a decrease in Notch activity, together with reduced expression of Eph receptors, which are key players in synaptic activity. The reduction in Eph is also found in PrPC-depleted cells. Hence, our observation of a similar signature of PrPC depletion and prion infection strengthens the view that PrPSc diverts PrPC function. We found a restoration of Notch and Eph effectors expression in response to histone deacetylase (HDAC) inhibitors, both in PrPC-depleted and prion-infected cells, suggesting that epigenetic mechanisms are involved in the PrP-dependent transcriptional control of these genes. This work provides a foundation for assessing a beneficial effect of HDAC inhibition in prion-infected mice and thereby defining whether HDAC could represent novel therapeutic targets to combat TSEs.

Príons são proteínas que causam um grupo de doenças neurodegenerativas invariavelmente fatais, sendo uma das mais conhecidas a encefalopatia espongiforme bovina (ou doença da vaca louca). A proteína príon celular (PrPc), rica em estrutura α-helicoidal, sofre uma mudança na sua estrutura secundária produzindo a proteína patológica (PrPSc; o príon) na qual prevalecem folhas-β. Devido à falta de dados estruturais de alta resolução dos príons, simulações de dinâmica molecular (DM) podem ser particularmente úteis para estudar o redobramento de PrP. Estudos experimentais e computacionais, descritos na literatura, indicam que a utilização de pH ácido é capaz de criar certa instabilidade estrutural, produzindo um ganho de estrutura-β na região N-terminal antes desestruturada. Este trabalho se propõe a investigar computacionalmente as mudanças estruturais na proteína príon celular do hamster Sírio induzidas por alteração de pH. Para isso, foi avaliada a influência de diferentes campos de força (GROMOS96 53a6, GROMOS96 43a1, AMBER99SB, AMBER99SB-ILDN, CHARMM27 e OPLS) simulados para as condições de pH neutro e ácido. A partir das análises, observou-se uma forte dependência dos resultados com o campo de força empregado. Além disso, somente os campos de força GROMOS96 53a6 e AMBER99SB demonstraram tendência à expansão do núcleo de folhas-β na região N-terminal da proteína simulada sob pH ácido e conseguiram representar adequadamente a condição neutra. As estruturas correspondentes a esses campos de força em pH ácido, foram, então, utilizadas como ponto de partida para novas simulações de DM em pH neutro (pH 7,4). Essa situação de retorno ao pH neutro ocorre quando o príon sai do compartimento endossomal (submetido a pH ácido) e retorna à superfície externa celular (onde estaria submetida novamente a pH neutro). Os resultados desse estudo de retorno ao pH neutro apontaram para a não reversibilidade de PrPSc, com a manutenção da cauda N-terminal voltada para a extremidade N-terminal da α-hélice HB. / Prions are proteins that cause a group of invariably fatal neurodegenerative diseases, one of the most known being bovine spongiform encephalopathy (or mad cow disease). The cellular prion protein (PrPC), rich in α-helical structure, undergoes a change in its secondary structure producing the pathological protein (PrPSc; the prion) in which β-sheet prevails. Due to the lack of high resolution structural data of the prions, molecular dynamics simulations (MD) may be particularly useful to study the refolding of PrP. Experimental and computational studies, described in the literature, indicate that the use of acidic pH is capable to create some structural instability, producing a gain of β-structure in the previously unstructured N-terminal region. This work proposes to investigate computationally the structural changes in the cellular prion protein of the Syrian hamster induced by pH change. For this, the influence of different force fields (GROMOS96 53a6, GROMOS96 43a1, AMBER99SB, AMBER99SB-ILDN, CHARMM27 and OPLS) were evaluated for neutral and acid pH conditions. From the analysis, a strong dependence of the results with the force field was observed. In addition, only the GROMOS96 53a6 and AMBER99SB force fields showed a tendency to expand the β-sheet nucleus in the N-terminal region of the simulated protein under acid pH and were able to adequately represent the neutral condition. The structures corresponding to these force fields under acidic pH were then used as the starting point for new MD simulations under neutral pH. This situation of return to the neutral pH occurs when the prion leaves the endosomal compartment (submitted to acid pH) and returns to the external cellular surface (where it would be submitted again to neutral pH). The results of this neutral pH return study pointed to the non-reversibility of PrPSc, with the maintenance of the N-terminal tail facing the N-terminal end of the α-helix HB.

A proteína prion celular (PrPC) consiste em uma glicoproteína de membrana que atua como receptora para diversas moléculas, desencadeando sinais intracelulares. Ao interagir com a co-chaperona STIP1, PrPC promove a autorrenovação e proliferação de células-tronco/progenitoras neurais (NSPCs) durante a fase embrionária. De fato, PrPC tem se destacado por sua participação na neurogênese embrionária e adulta, porém o papel de sua interação com a proteína STIP1 na neurogênese adulta permanece obscuro. Deste modo, o presente trabalho adotou abordagens in vitro para avaliação do complexo PrPC-STIP1 em processos celulares que culminam na neurogênese adulta. Para isso, culturas primárias de NSPCs de camundongos deficientes (Prnp-/-) e tipo-selvagens (Prnp+/+) para PrPC foram realizadas, e a cultura foi devidamente padronizada e caracterizada. Através de ensaios de autorrenovação, proliferação e migração celular sugere-se que PrPC promove estes eventos celulares independentemente de STIP1, e que possivelmente a proteína laminina seja um alvo crítico para migração via PrPC. / Cellular prion protein (PrPC) consists in a membrane glycoprotein that acts as a receptor to several molecules, triggering intracellular signals. By interacting with co-chaperone STIP1, PrPC promotes self-renewal and proliferation of neural stem/progenitor cells (NSPCs) during embryonic stage. Indeed, PrPC has excelled for its participation in embryonic and adult neurogenesis, but the role of its interaction with STIP1 protein in adult neurogenesis remains unclear. Thus, herein it was adopted in vitro approaches in order to evaluate the PrPC-STIP1 complex on cellular processes that culminate in adult neurogenesis. In order to assess that, NSPC primary cultures of PrPC deficient (Prnp-/-) and wild-type (Prnp+/+) mice were performed, and the culture was properly standardized and characterized. Through self-renewal, proliferation and cell migration assays, it was suggested that PrPC promotes these cellular events regardless of STIP1, and possibly the laminin protein is a critical target for migration via PrPC.

Les maladies à prions sont des pathologies neurodégénératives d’évolution fatale, transmissibles, pour lesquelles aucun traitement efficace n’existe. Elles associent sur le plan neuropathologique une spongiose, une gliose astrocytaire, une perte neuronale, et une accumulation de la forme anormalement repliée (PrPsc) de la protéine prion cellulaire codée par l’hôte. Certaines formes de cette maladie sont associées à une tauopathie et présentent des lésions neuropathologiques similaires à celles retrouvées dans la maladie d’Alzheimer (MA).Nous avons utilisé un modèle de cultures primaires de neurones afin d’explorer d’une part la relation entre la protéine prion et la physiopathologie de la protéine tau, et d’étudier d’autre part la propagation de souches humaines et l’effet de composés anti-prions sur cette propagation. Nos résultats indiquent que l’hyperphosphorylation de tau en réponse à l’exposition de PrP recombinantes est mutation dépendante, conformation dépendante, partiellement dépendante de la PrPc et est médiée par la kinase PDK1. Nous avons aussi démontré pour la première fois que la propagation d’isolats humains de maladie de Creutzfeldt-Jakob est possible dans un modèle in vitro et permet une évaluation rapide de l’efficacité de composés anti-prions, confirmée in vivo. Ces travaux ont permis de mieux caractériser la relation protéine amyloïde-physiopathologie de tau, d’ouvrir des perspectives de recherche dans la compréhension des mécanismes impliqués dans la MA, et d’apporter un modèle unique permettant d’évaluer rapidement les effets de molécules anti-prions vis-à-vis des souches les plus pertinentes, dans une stratégie de repositionnement thérapeutique. / Prion diseases are fatal transmissible neurodegenerative disorders, with no effective treatment. Brain lesions include neuronal vacuolization, astrogliosis, neuronal loss and the accumulation of PrPSc, an abnormal isoform of the host-encoded cellular prion protein (PrPc). Some forms of prion diseases are associated with tau fibrillar pathology similar to that observed in Alzheimer’s disease except that Abeta peptides are replaced by PrPsc. Here we used a primary neuronal cultures to first explore the interplay between the formation of prion protein assemblies and the occurrence of tau pathology, and secondly to evaluate in vitro human strain propagation and the efficiency of some antiprion compounds towards human prions. We showed that tau hyperphosphorylation in response to recombinant PrPs exposition was mutation-dependent, conformation-dependent and varied with the PrPc expression level of exposed neurons. This effect was mediated by PDK1 kinase. We also demonstrated for the first time that human prion isolates could propagate in an in vitro model. This model was also useful to evaluate the efficacy of antiprion compounds that was further validated in vivo. Our results help us to better understand the amyloid protein-tau physiopathology interplay and provide a useful and unique tool for fast evaluation of therapeutic compounds active against human prion strains in a repositioning strategy in such rare but devastating diseases.

A conversão da proteína príon celular (PrPc) em sua isoforma anormal PrPsc está associada a uma série de doenças neurodegenerativas, genericamente designadas por doenças priônicas. Embora a literatura tenha enfatizado o estudo do PrPsc e o mecanismo de propagação das doenças de príon, pouco tem sido feito para o entendimento do papel fisiológico do PrPc. Em 1997 nosso grupo descreveu um receptor/ligante para o PrPc utilizando o princípio da hidropaticidade complementar. Neste trabalho isolamos e identificamos este ligante de PrPc como sendo a STI-1 (Stress Inducible Protein-1). In vitro, a STI-1interage com o PrPc de maneira específica, saturável e com alta afinidade (Kd=8x10-8M). Paralelamente, mostramos que o PrPc se liga ao domínio RNIAEIIKDI da laminina (Ln) (Kd=2x10-8M). O bloqueio de PrPc na superfície de neurônios hipocampais de embriões de ratos e camundongos, reduziu a neuritogênese induzida por Ln. Além disso, neurônios provenientes de animais PrP -/- são incapazes de estender neuritos sobre o peptídeo RNIAEIIKDI, sugerindo que o PrPc é o único receptor celular para este domínio da Ln. Estes dados indicam que a interação PrPc-Ln seja relevante nos fenômenos de adesão e diferenciação neuronais. A caracterização das interações PrPc-Ln e PrPc-STI-1 representa contribuições importantes para a elucidação do papel biológico do PrPc. / Conversion of the cellular prion protein (PrPc) to its abnormal isoform PrPsc is associated with some neurodegenerative and fatal diseases called prion diseases. Although the literature has been emphasizing the mechanism of PrPsc conversion and illness propagation, little attention has been given to the PrPc physiological role. In 1997, our group described a PrPc receptor/ligand based on the complementary hydropathy theory. Herein, we identify the PrPc receptor/ligand as STI-1, the Stress Inducible Protein-1. In vitro studies showed that STI-1 is a specific, saturable and high affinity ligand for PrPc (Kd=8x10-8M). In parallel, we demonstrated that PrPc interacts with RNIAEIIKDI domain of laminin (Ln) (Kd=2x10-8M). The blockage of PrPc, both from embryonic rats and mice hippocampal neuros, inhibited Ln-induced neurite outgrowth. In addition, neurons from PrPc null mice are unable to extend neurites on RNIAEIIKDI, suggesting that PrPc is the unique cellular receptor for this Ln domain. These data indicate that PrPc-Ln interaction is relevant for neuronal adhesion and differentiation. The characterization of PrPc-Ln and PrPc-STl-1 interactions represents important contributions for the elucidation of the PrPc physiological role.

Prions are infectious agents that cause fatal neurodegenerative diseases in the brain. The wide-accepted protein-only hypothesis states that the misfolded form of prion protein (PrP) is the sole constituent of prions, and the self-propagating process of PrP is considered to play a central role in prion pathogenesis. Prions are believed to propagate when a PrP assembly enters a cell and replicates to produce two or more fibrils, leading to an exponential increase in PrP aggregate number with time. However, the molecular basis of this process has not yet been established in detail. This prion-like replication is also suggested to be the mechanism in the development of other notorious neurodegenerative disorders, such as Alzheimer's and Parkinson's disease. In this thesis, I use single-aggregate imaging to study fibril fragmentation and elongation of individual murine PrP aggregates from seeded aggregation in vitro. From fluorescence imaging of individual PrP aggregates on the coverslip surface, elongation and fragmentation of the PrP assemblies have been directly observed. PrP elongation occurs via a structural conversion from a proteinase K (PK)-sensitive to PK-resistant conformer. Fibril fragmentation was found to be length-dependent and resulted in the formation of PK-sensitive fragments. To gain more insights into the mechanism of the spread of PrP, the quantified kinetic profiles allows the determination of the rate constants for these processes through the use of kinetic modelling. This enables the estimation of a simple framework for aggregate propagation through the brain, assuming that doubling of the aggregate number is rate-limiting. In contrast, the same method was applied to measurement for α-Synuclein (αS) aggregation, which has been suggested to be prion-like and is associated with Parkinson's disease. While αS aggregated by the same mechanism, it showed significantly slower elongation and fragmentation rate constants than PrP, leading to much slower replication rate. Furthermore, the measurements in αS aggregation has been extended to the cellular environment, I use super-resolution imaging to study the amplification of endogenous αS aggregation in cells and the transcellular spread of αS. Endogenous αS showed a clear amplification in number of aggregates with time after seed transduction, and the newly-formed αS aggregates are likely to spread through cell-to-cell transmission. The proteasome was demonstrated to possess a novel disaggregase function for αS fibrils and thus produce more seeds for further replication. It partially explains that αS aggregation in cells was found to replicate at a substantially faster rate than that in vitro. Determining the nature of the oligomers formed during aggregation has been experimentally difficult due to the lack of suitable methods capable of detecting and characterising the low level of oligomers. To address this problem, I have studied the early formation of PrP oligomers formed during aggregation in vitro using various single-molecule methods. The early aggregation of PrP is observed to form a thioflavin T (ThT)-inactive and two ThT-active species of oligomers, which differ in size and temporal evolution. The ThT-active oligomers undergo a structural conversion from a PK-sensitive to PK-resistant conformer, while a fraction of which grow into mature fibrils. These results also enable the establishment of a kinetic framework for elucidating temporal evolution of PrP aggregation and the relationship between oligomers and fibrils. Overall, my research identifies fibril elongation with fragmentation are the key molecular processes leading to PrP and αS aggregate replication, an important concept in prion biology, and provides a simple framework to estimate the rate of prion and prion-like spreading in animals. The results also show that a diverse range of oligomers is formed and co-exist during PrP aggregation which differ both in their structure and properties and provides mechanistic insights into a prion aggregation. The work provides a new quantitative approach to describe the prion-like property in neurodegenerative diseases from a kinetic perspective that can be verified in extending studies in other proteins or in cells.

Prions are self-perpetuating and, in most cases, aggregation-prone protein isoforms that transmit neurodegenerative diseases in mammals and control heritable traits in yeast. Prion conversion requires a very high level of identity of the interacting protein sequences. Decreased transmission of the prion state between divergent proteins is termed "species barrier" and was thought to occur due to the inability of divergent prion proteins to co-aggregate. Species barrier can be overcome in cross-species infections, for example from "mad cows" to humans. We studied the counterparts of yeast prion protein Sup35, originated from three different species of the Saccharomyces sensu stricto group and exhibiting the range of prion domain divergence that overlaps with the range of divergence observed among distant mammalian species. Heterologous Sup35 proteins co-aggregated in S. cerevisiae cells. However, in vivo cross-species prion conversion was decreased and in vitro polymerization was cross-inhibited in at least some heterologous combinations, thus demonstrating the existence of prion species barrier. Our data suggests that species-specificity of prion transmission is controlled at the level of conformational transition rather than co-aggregation. We have shown the Sup35 prion domain is sufficient for the species barrier among the S. sensu stricto species, and constructed SUP35 chimeric prion domains, combining the subregions of various origins Our data demonstrated in different cross-species combinations, different modules of prion domain play a crucial role in the controlling of species-specificity of prion transmission. One essential amino acid position has been identified in S. cerevisiae and S. paradoxus system. Our data support a model suggesting that identity of the short amyloidogenic sequences is crucial for the species barrier. Sup35 originated from three different species of the S. sensu stricto group were capable of forming a prion in S. cerevisiae. However, it was not known whether they are capable of generating and maintaining the prion state in the homologous cell environment. We have constructed the S. paradoxus and S. bayanus strains with appropriate markers, and we were able to demonstrate de novo [PSI+] formation in S. paradoxus but not in S. bayanus. Our data show that [PSI+] formation is not a unique property of S. cerevisiae.

A proteína prion celular (PrPC) consiste em uma glicoproteína de membrana que atua como receptora para diversas moléculas, desencadeando sinais intracelulares. Ao interagir com a co-chaperona STIP1, PrPC promove a autorrenovação e proliferação de células-tronco/progenitoras neurais (NSPCs) durante a fase embrionária. De fato, PrPC tem se destacado por sua participação na neurogênese embrionária e adulta, porém o papel de sua interação com a proteína STIP1 na neurogênese adulta permanece obscuro. Deste modo, o presente trabalho adotou abordagens in vitro para avaliação do complexo PrPC-STIP1 em processos celulares que culminam na neurogênese adulta. Para isso, culturas primárias de NSPCs de camundongos deficientes (Prnp-/-) e tipo-selvagens (Prnp+/+) para PrPC foram realizadas, e a cultura foi devidamente padronizada e caracterizada. Através de ensaios de autorrenovação, proliferação e migração celular sugere-se que PrPC promove estes eventos celulares independentemente de STIP1, e que possivelmente a proteína laminina seja um alvo crítico para migração via PrPC. / Cellular prion protein (PrPC) consists in a membrane glycoprotein that acts as a receptor to several molecules, triggering intracellular signals. By interacting with co-chaperone STIP1, PrPC promotes self-renewal and proliferation of neural stem/progenitor cells (NSPCs) during embryonic stage. Indeed, PrPC has excelled for its participation in embryonic and adult neurogenesis, but the role of its interaction with STIP1 protein in adult neurogenesis remains unclear. Thus, herein it was adopted in vitro approaches in order to evaluate the PrPC-STIP1 complex on cellular processes that culminate in adult neurogenesis. In order to assess that, NSPC primary cultures of PrPC deficient (Prnp-/-) and wild-type (Prnp+/+) mice were performed, and the culture was properly standardized and characterized. Through self-renewal, proliferation and cell migration assays, it was suggested that PrPC promotes these cellular events regardless of STIP1, and possibly the laminin protein is a critical target for migration via PrPC.

A conversão da proteína príon celular (PrPc) em sua isoforma anormal PrPsc está associada a uma série de doenças neurodegenerativas, genericamente designadas por doenças priônicas. Embora a literatura tenha enfatizado o estudo do PrPsc e o mecanismo de propagação das doenças de príon, pouco tem sido feito para o entendimento do papel fisiológico do PrPc. Em 1997 nosso grupo descreveu um receptor/ligante para o PrPc utilizando o princípio da hidropaticidade complementar. Neste trabalho isolamos e identificamos este ligante de PrPc como sendo a STI-1 (Stress Inducible Protein-1). In vitro, a STI-1interage com o PrPc de maneira específica, saturável e com alta afinidade (Kd=8x10-8M). Paralelamente, mostramos que o PrPc se liga ao domínio RNIAEIIKDI da laminina (Ln) (Kd=2x10-8M). O bloqueio de PrPc na superfície de neurônios hipocampais de embriões de ratos e camundongos, reduziu a neuritogênese induzida por Ln. Além disso, neurônios provenientes de animais PrP -/- são incapazes de estender neuritos sobre o peptídeo RNIAEIIKDI, sugerindo que o PrPc é o único receptor celular para este domínio da Ln. Estes dados indicam que a interação PrPc-Ln seja relevante nos fenômenos de adesão e diferenciação neuronais. A caracterização das interações PrPc-Ln e PrPc-STI-1 representa contribuições importantes para a elucidação do papel biológico do PrPc. / Conversion of the cellular prion protein (PrPc) to its abnormal isoform PrPsc is associated with some neurodegenerative and fatal diseases called prion diseases. Although the literature has been emphasizing the mechanism of PrPsc conversion and illness propagation, little attention has been given to the PrPc physiological role. In 1997, our group described a PrPc receptor/ligand based on the complementary hydropathy theory. Herein, we identify the PrPc receptor/ligand as STI-1, the Stress Inducible Protein-1. In vitro studies showed that STI-1 is a specific, saturable and high affinity ligand for PrPc (Kd=8x10-8M). In parallel, we demonstrated that PrPc interacts with RNIAEIIKDI domain of laminin (Ln) (Kd=2x10-8M). The blockage of PrPc, both from embryonic rats and mice hippocampal neuros, inhibited Ln-induced neurite outgrowth. In addition, neurons from PrPc null mice are unable to extend neurites on RNIAEIIKDI, suggesting that PrPc is the unique cellular receptor for this Ln domain. These data indicate that PrPc-Ln interaction is relevant for neuronal adhesion and differentiation. The characterization of PrPc-Ln and PrPc-STl-1 interactions represents important contributions for the elucidation of the PrPc physiological role.